文献速递胸部肿瘤

非小细胞肺癌中程序性死亡配体1拷贝数缺失与肿瘤染色减少及冷免疫表型相关

Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
PubMed 文献 · J Thorac Oncol · 2022-02-04

本研究通过实时聚合酶链反应检测手术切除的非小细胞肺癌标本(n=87)及对照活检(n=20)中PD-L1拷贝数和mRNA表达,并分析另一组支气管镜活检标本(n=15)。发现PD-L1拷贝数缺失(15/87=17%)与肿瘤细胞PD-L1染色减少及炎症/免疫抑制介质表达降低相关,且拷贝数在不同解剖部位间高度稳定,可能作为预测免疫治疗反应的生物标志物。

要点

  • PD-L1拷贝数缺失见于17%(15/87)手术切除NSCLC标本,拷贝数增加见于7%(5/87)。
  • 低PD-L1拷贝数肿瘤的干扰素-γ、IL-6、IL-1β、MMP-9及IL-10、TGF-β表达显著降低。
  • PD-L1拷贝数在不同解剖部位间变异低,而PD-L1 mRNA表达变异较大。

核心结论

  • 低PD-L1拷贝数肿瘤表现为PD-L1表达降低、肿瘤细胞PD-L1染色减少及免疫冷肿瘤微环境。

研究设计与样本

  • 研究检测手术切除NSCLC肿瘤活检(n=87)和对照活检(n=20)中PD-L1基因拷贝数与mRNA表达,并分析第二组支气管镜来源肿瘤活检(n=15),包括同一患者不同解剖部位的多份活检。

主要发现

  • PD-L1 mRNA水平与PD-L1肿瘤染色强相关(r=0.55,p<0.0001)。
  • 干扰素-γ mRNA表达与PD-L1免疫细胞染色相关,但与PD-L1肿瘤细胞染色无关。
  • PD-L1拷贝数与PD-L1肿瘤染色正相关,但与PD-L1免疫细胞染色无关。
  • PD-L1拷贝数分析检测到缺失(15/87=17%)和增加(5/87=7%)。
  • 低PD-L1拷贝数肿瘤的炎症介质(干扰素-γ、IL-6、IL-1β、MMP-9)和免疫抑制介质(IL-10、TGF-β)表达水平显著降低。

关键数值与推荐

  • PD-L1 mRNA与肿瘤染色相关系数r=0.55,p<0.0001。
  • PD-L1拷贝数缺失频率15/87=17%,增加频率5/87=7%。

临床怎么用

  • 作者认为PD-L1拷贝数在不同肿瘤区域高度稳定,其评估可能作为预测免疫治疗反应的稳健且互补的生物标志物,低拷贝数可能预测无反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Programmed death-ligand 1 (PD-L1) copy number gains may be predictive of clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number variations in tumor resection and bronchoscopy biopsies and its relationship with PD-L1 tumor cell staining and inflammatory gene expression. METHODS: PD-L1 gene copy number and mRNA expression were evaluated by real-time polymerase chain reaction in surgically resected NSCLC tumor biopsies (n = 87) and control biopsies (n = 20). A second cohort (n = 15) of bronchoscopy-derived tumor biopsies was analyzed, including multiple biopsies from the same patient across different anatomical sites. RESULTS: PD-L1 mRNA levels strongly correlated with PD-L1 tumor staining (r = 0.55, p < 0.0001). Interferon-γ mRNA expression associated with PD-L1 immune cell staining, but not PD-L1 tumor cell staining. In contrast, PD-L1 copy number positively associated PD-L1 tumor staining, but not PD-L1 immune cell staining. PD-L1 copy number analysis detected loss (15 of 87 = 17%) and gain (5 of 87 = 7%) of copy number. Tumors with low PD-L1 copy number expressed significantly reduced levels of inflammatory (interferon-γ, interleukin [IL]-6, IL-1β, MMP-9) and immunosuppressive (IL-10, transforming growth factor β) mediators. Analysis of bronchoscopy-derived biopsies revealed low heterogeneity in copy number values across different anatomical sites, in contrast to more variable PD-L1 mRNA expression. CONCLUSIONS: Low PD-L1 copy number tumors display reduced PD-L1 expression, reduced PD-L1 tumor cell staining, and an immunologic cold tumor microenvironment. Because PD-L1 copy number values are highly stable across different tumor regions, its evaluation may represent a robust and complimentary biomarker for predicting response to immunotherapy, where low copy number may predict lack of response.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Aujla S, Aloe C, Vannitamby A, et al. Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype. J Thorac Oncol. 2022. PMID: 35124252. doi:10.1016/j.jtho.2022.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。